New investors in the firm included Novartis Venture Fund and Aventis Capital, the venture arms of Novartis and Sanofi-Aventis, respectively. Previous investors Arch Venture Partners, MPM Capital, Venrock Associates, and Versant Ventures also participated in the recent round of financing.
Research Triangle Park, NC-based Amphora has developed a platform for drug discovery that integrates its own compound purification, characterization, and quantification technology, microplate processing system, and Caliper Technologies' microfluidics.
Amphora offers drug firms target-based discovery and pathway profiling services based on the technology. The firm also is developing a pipeline of small-molecule therapeutics, which are currently in preclinical development.
Two years ago, Amphora raised $23 million in a Series B round of venture funding.